knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 11:03:09 - browse：71257

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： ‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

WSS

Sickle cell gene therapy cures need to be accessible in Africa

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Blinken talks high

The aspartame in Diet Coke probably isn’t giving you cancer

Inflation cooled significantly in June, bringing price hikes close to normal levels

China sends large group of warplanes, navy ships towards Taiwan in forceful display

explore

knowledge

Wikipedia

Cancer drug shortages should be causing more outrage

Biden targets hefty hospital 'facility fees' that often surprise patients

How to save PrEP access — and even expand it

The U.S. needs a new definition of substance use “recovery”

Malaria cases in Florida and Texas: Here’s what you need to know

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Recent heat wave in the Mediterranean caused by climate change: Study

Affirmative action in medical school literally saved lives

How are insurers handling Leqembi and related scans?

explore

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Eisai exec who led development of Alzheimer’s drug to retire

ACA's risk program benefits Blue Cross Blue Shield insurers

Digital health funding stays low as a new reality sets in

The aspartame in Diet Coke probably isn’t giving you cancer

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

knowledge

hotspot

knowledge

knowledge